Vantictumab, formerly identified as OMP18R5, represents the novel cloned agent designed for specifically inhibit bone associated protein 18R5. The approach is actively developed by researchers for possible uses in several orthopedic disorders, particularly situations involving increased osseous loss. Preclinical studies suggest Vantictumab can effe